Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
2019
Objectives
To compare the cost-effectiveness of first-line gefitinib, erlotinib, afatinib, and osimertinib in patients with non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
58
References
15
Citations
NaN
KQI